Document is current
Any future updates will be listed below
-
Authors
Kandarpa, Malathi
Peterson, Luke F.
Potu, Harish
Ramappan, Megha
Liu, Yihong
Polk, Avery
Wang, Shaomeng https://orcid.org/0000-0002-8782-6950
Talpaz, Moshe https://orcid.org/0000-0003-3361-3981
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA219345)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA219345)
Thomas H. Brown Research Fund for Blood Cancers
- License Information
-
More Information
Article History
Received: 29 October 2025
Revised: 26 February 2026
Accepted: 27 March 2026
First Online: 15 April 2026
Competing interests
: The authors declare the following competing financial interest(s): The University of Michigan has filed patent applications on this MDM2 degrader, which have been licensed to Ascentage Pharma Group. S Wang is a co-inventor on one or more of these patent applications. S Wang was a co-founder of Ascentage, owns equity in Ascentage and is a paid consultant to Ascentage. The University of Michigan has also received a research contract from Ascentage.
